In vivo anti-tumor effects of SAMMSON knockdown were evaluated in three independent experiments using two UM patient derived xenografts (PDX) models (MP46 (GNAQQ209L) and MEL077 (derived from a patient progressing on the immune checkpoint inhibitor pembrolizumab)) showing high SAMMSON expression levels (Fig. 1D). This evidence concerns the gene SAMMSON and neoplasm.